“…While SFT has been acknowledged as a suitable niche for harboring metastases because of its rich vascularity to lter microemboli from other tumors, SFT is an extraordinarily rare recipient for tumor-to-tumor metastasis. To date, only nine SFT recipients of tumor-to-tumor metastasis have been described in the literature (Table 1), including ve intrathoracic lesions, one intraabdominal, one spinal intradural, and two in the soft tissues (thigh and back) [2][3][4][5][6][7][8][9][10]. The most common metastatic donor to SFT in previous reports was breast cancer.…”